SciBase obtained approval from the FDA for Nevisense, a device designed to facilitate detection of early stages of malignant melanoma. The device, which conducts skin assessment using electrical signals, may be used for prebiopsy assessment of suspicious skin lesions that have at least one characteristic of melanoma, but it should not be used for confirming a clinical diagnosis of melanoma.
SciBase's melanoma detection device wins FDA approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.